




























Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Ratnasothy, K., Jacob, J., Tung, S. L., Boardman, D. A., Lechler, R. I., Sanchez Fueyo, A., ... Lombardi, G.
(2019). IL-2 therapy preferentially expands adoptively transferred donor-specific Tregs improving skin allograft
survival. American Journal of Transplantation, 19(7), 2092-2100. https://doi.org/10.1111/ajt.15306
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 13. Aug. 2019

2092  |    Am J Transplant. 2019;19:2092–2100.amjtransplant.com
 
Received: 3 August 2018  |  Revised: 4 January 2019  |  Accepted: 26 January 2019
DOI: 10.1111/ajt.15306  
B R I E F  C O M M U N I C A T I O N
IL‐2 therapy preferentially expands adoptively transferred 
donor‐specific Tregs improving skin allograft survival
Kulachelvy Ratnasothy1 |   Jacintha Jacob1 |   Sim Tung1 |   Dominic Boardman1 |    
Robert Ian Lechler1 |   Alberto Sanchez‐Fueyo2 |   Marc Martinez‐Llordella2 |   
Giovanna Lombardi1
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© 2019 The Authors American Journal of Transplantation published by Wiley Periodicals, Inc. on behalf of The American Society of Transplantation and the 
American Society of Transplant Surgeons
Marc Martinez‐Llordella and Giovanna Lombardi share senior coauthorship.
Abbreviations: APC, antigen presenting cells; CNIs, calcineurin inhibitors; GvHD, graft‐versus‐host disease; IL‐2, interleukin‐2; IL‐2c, interleukin‐2 complexes; IS, immunosuppression; 
SEM, standard error of the mean; TCR, T cell receptor; Teffs, effector T cells; Tregs, regulatory T cells.
1MRC Centre for Transplantation, Peter 
Gorer Department of 
Immunobiology, Faculty of Life Sciences & 
Medicine, King's College London, London, 
UK
2Department of Inflammation Biology, MRC 
Centre for Transplantation, Institute of 
Liver Studies, Faculty of Life Sciences & 
Medicine, King's College London, London, 
UK
Correspondence
Giovanna Lombardi and Marc Martinez‐
Llordella
Emails: giovanna.lombardi@kcl.ac.uk and 
marc.martinez‐llordella@kcl.ac.uk
Funding information
King's Health Par; National Institute for 
Health Research; British Heart Foundation
Regulatory T cells (Tregs) have unique immunosuppressive properties and are essen‐
tial to ensure effective immunoregulation. In animal models, Tregs have been shown 
to prevent autoimmune disorders and establish transplantation tolerance. Therefore, 
the prospect of harnessing Tregs, either by increasing their frequency or by confer‐
ring allospecificity, has prompted a growing interest in the development of immuno‐
therapies. Here, employing a well‐established skin transplant model with a single 
major histocompatibility complex mismatch, we compared the therapeutic efficacy 
of adoptively transfer Treg with or without donor specificity and the administration 
of IL‐2 to promote in vivo expansion of Treg. We showed that IL‐2 treatment prefer‐
entially enhances the proliferation of the allospecific Tregs adoptively transferred in 
an antigen‐dependent manner. In addition, donor‐specific Tregs significantly in‐
creased the expression of regulatory‐related marker, such as CTLA4 and inducible 
costimulator (ICOS), in the skin allograft and draining lymph nodes compared to en‐
dogenous and polyclonal transferred Tregs. Importantly, by combining IL‐2 with 
donor‐specific Tregs, but not with polyclonal Tregs, a synergistic effect in prolonging 
skin allograft survival was observed. Altogether, our data suggest that this combina‐
tion therapy could provide the appropriate conditions to enhance the immunoregula‐
tion of alloimmune responses in clinical transplantation.
K E Y W O R D S
antigen presentation/recognition, basic (laboratory) research/science, graft survival, immune 
regulation, immunobiology, immunosuppression/immune modulation, organ transplantation 
in general, T cell biology, tolerance, translational research/science
1  | INTRODUC TION
CD4+CD25+FoxP3+ regulatory T cells (Tregs) play a critical role 
in various immunological processes, and are responsible for the 
induction and maintenance of peripheral tolerance to both self and 
foreign antigens. In preclinical models, adoptive transfer of Tregs 
has been exploited to prevent autoimmune diseases and to pro‐
mote transplantation tolerance by modulating the balance between 
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pathogenic and regulatory immune responses.1 The clinical applica‐
tion of ex vivo expanded Tregs has been initially developed to inhibit 
graft‐versus‐host disease (GvHD) following stem cell transplantation 
and to prevent disease progression in Type 1 diabetes.2‐4 More re‐
cently, the first clinical trials in renal transplant recipients have been 
published demonstrating that the injection of polyclonal expanded 
Tregs shortly after transplantation is safe and feasible.5,6 Although, 
we have observed similar results in the completed clinical trials in 
kidney (the ONE Study) and liver (ThRIL) transplantation,7 the clini‐
cal efficacy of Treg transfer in promoting transplantation tolerance 
remains unproven.
Linked to the increased understanding about the mechanisms of 
graft rejection, we and others have demonstrated in preclinical mod‐
els of transplantation that the adoptive transfer of murine Tregs with 
donor specificity was superior in promoting allograft survival com‐
pared to polyclonal Tregs.8,9 We have extended these observations 
to human Tregs by showing in a humanized mouse model of human 
skin transplantation that Tregs generated by stimulation with donor 
antigen presenting cells (APC) were superior in protecting from 
skin graft damage compared to polyclonally expanded Tregs.10,11 
Although new trials are currently testing the applicability of donor‐
specific Tregs in kidney and liver transplantation, the general view is 
that the exclusive transfer of Tregs alone is unlikely to be sufficient 
to induce transplantation tolerance and therefore combination ther‐
apies are required.
Interleukin‐2 (IL‐2) is essential for the optimal development, sur‐
vival, and function of Tregs. In contrast to effector T cells (Teffs), 
resting Tregs constitutively express the high‐affinity IL‐2Rα (CD25), 
which makes them highly sensitive to very low doses of IL‐2. Binding 
to the IL‐2 receptor complex initiates sequential signaling events, in‐
cluding phosphorylation of STAT5, that result in transcriptional acti‐
vation of immunoregulatory genes such as FOXP3 and CD25 itself, 
and prosurvival genes such as MCL1 and BCL2. In animal models 
of skin transplantation, lupus nephritis, and lung inflammation it has 
been shown that the administration of either low‐dose IL‐2 or rIL‐2/
anti‐IL‐2 complexes (IL‐2c) increased the endogenous pool of Tregs 
and improved disease outcome.12‐14 We have recently published that 
although calcineurin inhibitors (CNIs) markedly disrupt Treg homeo‐
stasis and have a negative impact on the most highly immunosup‐
pressive Treg subsets, provision of exogenous IL‐2 reversed these 
effects and synergized with CNIs in neutralizing effector T cell re‐
sponses and promoting allograft survival.15 In the clinic, increasing 
studies in patients with autoimmunity or GvHD have shown that 
low‐dose IL‐2 safely expands endogenous Tregs providing significant 
therapeutic benefits.16‐19.
In this study, we compared the efficacy of the different strate‐
gies proposed to modulate the Treg pool that can be translated into 
the clinical setting. Employing a very well‐established skin transplant 
model in which the skin is mismatched with the recipient for one 
single major histocompatibility complex class I molecule (Kd), we 
demonstrated that IL‐2 treatment preferentially expands adoptively 
transferred in vitro generated donor‐specific Tregs leading to a syn‐
ergist effect in extending graft survival.
2  | MATERIAL S AND METHODS
2.1 | Mice
BL/6 (H‐2b) and CBA (H‐2k) mice aged 6‐8 weeks old were purchased 
from Charles River Laboratories. BL/6 Kd (BL/6 transgenic for Kd), 
TCR75 (T cell receptor [TCR]‐transgenic mice recognizing Kd pep‐
tide H‐2Ab), CD45.1 congenic mice on a BL/6 background were bred 
and maintained in the Biological Services Unit (New Hunt House) of 
King's College London. All animal experiments were performed ac‐
cording to UK Home Office.
2.2 | Skin transplantation and treatments
Skin transplants were performed and monitored as described pre‐
viously.8 In humans, low doses of rIL‐2 (0.5‐3 million IU/m2 day) 
increases the proportion and absolute number of circulating Tregs 
more than 2‐fold,20,21 but in mice this increase is observed only fol‐
lowing administration of rIL‐2/anti–IL‐2 antibody complexes (IL‐2c).15 
IL‐2c was prepared by incubating 1 μg recombinant mouse IL2 (eBio‐
science) with 9 μg of functional grade purified antimouse IL‐2 (clone 
JES6‐1A12, eBioscience) for 30 minutes at 37°C, and it was injected 
intraperitoneally on days 0, 1, 2, and 3 posttransplant. For CD8 
depletion, anti‐CD8 antibody (clone YTS 169, 250 μg/mice) was in‐
jected intraperitoneally day ‐1, +1, +7 posttransplant.
2.3 | Generation and maintenance of CD4+CD25+ 
Treg lines
Previously generated autoreactive and indirect allospecificity 
Treg lines were used.8,9 Briefly, B6‐S Tregs were generated by re‐
peated stimulation with autologous BL/6 DCs and B6‐Kd Tregs 
were obtained after transduction with a TCR specific for Kd pep‐
tide presented by H‐2Ab. Treg lines were maintained as described 
previously.8
2.4 | Statistical analysis
The statistical analysis was performed by using GraphPad Prism 
6 software (GraphPad Software Inc). Student's t test was used for 
comparison between two groups and analysis of variance with 
Tukey's post hoc correction for pairwise comparisons was used to 
compare more than 2 groups (*P < .05, **P < .01, ***P < .001 and 
****P < .0001). Mean ± standard error of the mean (SEM) was rou‐
tinely used.
3  | RESULTS
3.1 | TCR‐transduced Tregs are highly specific for 
the Kd alloantigen
To assess the effect of combining adoptive transfer of in vitro ex‐
panded Tregs with IL‐2 therapy, we employed two different Treg 
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lines that we have reported previously,8,9 one with self‐specificity 
(B6‐S Tregs) and the other with indirect allospecificity for Kd peptides 
presented by H‐2Ab (B6‐Kd Tregs). When subjected to flow cytomet‐
ric analysis, both cell lines showed similar expression of markers re‐
lated to regulatory function (Figure 1A). Next, the function of the 
two Treg lines was evaluated by measuring the suppressive effect on 
the proliferation of CFSE‐labeled effector BL/6 CD4+ T cells cocul‐
tured in the presence of autologous APC and anti‐CD3 (Figure 1B). 
Polyclonal proliferation of responder T cells was inhibited in a 
dose‐dependent manner and the percentages of suppression were 
comparable between the two Treg lines. The suppression of Kd‐spe‐
cific responses by the Treg lines was assessed by coculturing BL/6 
F I G U R E  1   T cell receptor‐transduced Tregs are highly specific for allogenic Kd antigens. A, Surface expression for CD25, GITR, CD44, 
CCR9, ICOS, PD1, CD73, and CD39 as well as intracellular FOXP3 and CTLA4 on the two Treg lines was determined by flow cytometry 
(representative staining of > 3 performed). B‐C, Representative histograms of the division of CFSE‐labeled effector BL/6 CD4+ T cells 3 days 
after coculture with BL/6 APC plus anti‐CD3 (B) or BL/6 APC plus Kd peptides (C) in the presence or not of the two Treg lines (left panels). 
The percentages of suppression capacity at 2:1 and 1:1 ratio (APC:Treg) is shown in the right panel. Results represent mean ± standard 
error of the mean of three independent experiments. APC, antigen presenting cells; BL/6, C57BL/6; CCR9, C‐C chemokine receptor type 
9; CFSE, carboxyfluorescein succinimidyl ester; CTLA4, cytotoxic T‐lymphocyte‐associated protein 4; FOXP3, Forkhead box p3+; GITR, 
glucocorticoid‐induced tumor necrosis factor receptor; ICOS, inducible costimulator; PD1, programmed cell death protein 1; Treg, regulatory 
T cell. **P < .01
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APC pulsed with a Kd peptide and CFSE‐labeled BL/6 RAG‐/‐TCR75 
CD4+ T cells, derived from TCR‐transgenic mice specific for Kd and 
restricted by Ab (Figure 1C). B6‐Kd Tregs showed an increased sup‐
pressive activity compared to the self‐reactive B6‐S Tregs in the 
inhibition of TCR75 T cell proliferation, further confirming the anti‐
gen‐specificity of the B6‐Kd Tregs.
3.2 | Combining Kd‐specific Tregs with IL‐2 therapy 
showed a synergistic effect in prolonging skin 
allograft survival
Having shown that B6‐S and B6‐Kd Treg lines were phenotypically 
similar and suppressive in vitro, we compared their immunoregula‐
tory function to the effect of endogenous Treg expansion caused 
by IL‐2 therapy in a transplant model where BL/6 mice were trans‐
planted with skins derived from BL/6.Kd donors. CD8 depletion was 
performed by anti‐CD8 antibody injection on day ‐1, 1 and 7 after 
transplantation to inhibit the direct allospecific response to intact 
Kd molecules, as previously published.8 Recipient mice were treated 
with 5x106 self‐specific B6‐S or donor‐specific B6‐Kd Tregs the day 
before transplant, or by IL‐2c injection from day 0 to day 3 follow‐
ing engraftment (Figure 2A). Although the self‐reactive Tregs were 
able to extend allograft survival only slightly (median: 13 vs 14 days), 
Kd‐specific Tregs prolonged the median skin survival from 13 to 
17 days (Figure 2B). Similarly, IL‐2c treatment showed significant 
prolongation of skin allograft survival (median 19 days).
Next, Treg adoptive transfer was combined with injection of IL‐2 
to evaluate whether increased prolongation of skin transplant sur‐
vival could be achieved (Figure 2C). Although combining IL‐2c treat‐
ment with self‐reactive Tregs did not increase the effect observed 
with IL‐2c alone, the combination of Kd‐specific Tregs and IL‐2c pro‐
longed allograft survival up to a median of 29 days. Altogether, these 
results demonstrate the advantage of combining Treg therapy with 
IL‐2 administration when antigen‐specific cells were used.
3.3 | IL‐2c amplifies the number of adoptive 
transferred Kd‐specific Tregs after skin 
transplantation
To assess the mechanisms behind the coordinated effect of IL‐2 
therapy and B6‐Kd Treg combination, we analyzed the transferred 
(CD45.2) and endogenous (CD45.1) Tregs in different tissues at 6 
and 10 days following skin transplantation in the same model de‐
scribed previously (Figure 3A). The analysis of blood samples 6 days 
after transplantation showed a significant increase in the total 
FOXP3+CD25+ Treg pool after IL‐2c treatment independently of 
adoptive transfer of Tregs (Figure 3B, left panel). However, when the 
percentages of transferred Tregs were evaluated, preferential ex‐
pansion of the B6‐Kd Tregs compared to B6‐S, particularly after IL‐2c 
treatment, was observed (Figure 3B, right panel). CD25 expression 
was similar between the two Treg lines, suggesting that the distinc‐
tive expansion of B6‐Kd Tregs was not due to differential sensitivity 
to IL‐2 (Figure 3C).
The same analysis of Tregs was performed in the spleen, draining 
lymph nodes and skin on day 10 after transplantation. The frequen‐
cies of total Tregs were similar between all groups, indicating that 
the transferred Tregs did not alter the global distribution of Tregs 
among CD4+ T cells (Figure 3D, left panels). However, the analysis of 
adoptively transferred Treg lines showed a significant expansion of 
the Kd‐specific Tregs in all the tissues when Treg therapy was com‐
bined with IL‐2c treatment (Figure 3D, right panels). Although the 
total number of CD4+ T cell and Tregs in the different tissues was 
not significantly increased by the early IL‐2c treatment, the absolute 
cell counts of Kd‐specific Tregs were preferentially augmented in the 
skin allograft (Figure 3E & S1A).
3.4 | Characterization of adoptively 
transferred Tregs
The phenotypic stability of adoptively transferred Tregs was as‐
sessed by analyzing the percentage of FOXP3+ cells among the ex‐
ogenous CD4+CD45.2+ cells. Sequential blood samples from day 6 
F I G U R E  2   Kd‐specific Tregs synergizes with IL‐2 therapy in 
prolonging skin allograft survival. A, Schema of the allogeneic BL/6.
Kd skin transplant model. B‐C, Comparison of graft survival in mice 
with no cell transfer (PBS), B6‐S and B6‐Kd Tregs without (B) or 
with combination of IL‐2c treatment (C), as described in Materials 
and Methods. Results represent mean ± standard error of the mean 
of four independent experiments. B6‐Kd, Kd‐specific BL/6; B6‐S, 
Self‐specific BL/6; IL‐2, interleukin‐2; IL‐2c, interleukin‐2 complexes; 
Treg, regulatory T cell. *P < .05, ***P < .001, ****P < .0001 [Color 
figure can be viewed at wileyonlinelibrary.com]
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and day 10 after skin transplantation revealed that the frequency 
of FOXP3+ cells within the adoptively transferred Tregs was main‐
tained and this occurred independently of the IL‐2c treatment 
(Figure 4A). Similarly, Treg lineage preservation was observed in the 
spleen, draining lymph nodes and skin allograft at day 10 after trans‐
plantation (Figure S2A).
To further assess the functional characteristics of the two trans‐
ferred Treg lines, the expression of several Treg‐related markers was 
investigated on endogenous and exogenous Tregs at day 10 after 
skin transplantation. In the draining lymph nodes, donor‐specific B6‐
Kd Tregs showed an increased expression of CTLA4 and inducible co‐
stimulator compared to the endogenous and the self‐specific Tregs 
F I G U R E  3   IL‐2c amplifies the number of adoptive transferred Kd‐specific Tregs after skin transplantation. Tregs from different tissues 
were analyzed 6 and 10 days after BL/6‐Kd skin transplant to BL/6 mice receiving no cells, B6‐S or B6‐Kd Tregs in combination or not with 
IL‐2c. A, Representative dot plot of dLN CD4+ T cells based on CD25 and FOXP3 (left) and distribution of endogenous and exogenous Tregs 
based on CD45.1 and CD45.2 congenic markers (right). B, Percentage of total circulating Tregs among CD4+ T cells (left panel) and self‐ or 
donor‐specific Tregs among FOXP3 + cells (right panel) 6 days after transplantation in the presence of IL‐2c (black bar) or not (white bar). 
C, CD25 expression of blood Teffs, endogenous, B6‐S and B6‐Kd Tregs 6 days after transplantation. D, Percentages of total Tregs among 
CD4+ T cells (left panel) and self‐ or donor‐specific Tregs among FOXP3 + cells (right panel) 6 days after transplantation in the presence of 
IL‐2c (black bar) or not (white bar) in spleen, dLN and skin tissue. E, Cell count from skin allograft (0.5 cm2) of CD4 + (left panel), total Tregs 
(middle panel) and exogenous Tregs (right panel) 10 days after transplantation. Results represent mean ± SEM of at least three independent 
experiments. B6‐Kd, Kd‐specific BL/6; B6‐S, Self‐specific BL/6; dLN, draining lymph nodes; FOXP3, Forkhead box p3+; IL‐2, interleukin‐2; 
IL‐2c, interleukin‐2 complexes; PBS, phosphate‐buffered saline; Teff, effector T cells; Treg, regulatory T cell. *P < .05, **P < .01, ***P < .001, 
****P < .0001
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(Figure 4B); whereas no differences between the Treg lines were 
observed in the other tissues (Figure S2B). Although IL‐2c treatment 
augmented CD39 expression particularly in B6‐Kd Tregs (Figures 4B 
& S2B), no other major phenotypic effects were observed with the 
IL‐2 therapy, suggesting that the prolonged allograft survival in the 
combination therapy was due to the increased frequency of donor‐
specific Tregs in the inflamed tissues.
3.5 | Treg expansion during IL‐2c therapy is 
enhanced by antigen recognition
To determine the extent to which antigen‐specific recognition 
modulates the expansion of Treg during IL‐2 treatment, CFSE‐la‐
beled B6‐S and B6‐Kd Tregs were transferred to BL/6 or BL/6.Kd 
hosts. Mice were then treated with or without daily IL‐2c and Treg 
proliferation was evaluated 3 days after transfer (Figure 5A). The 
proliferation index of both Treg lines in BL/6 host mice was simi‐
lar independent of IL‐2 treatment (Figure 5A, right panels). In BL/6.
Kd hosts, however, although the proliferation of adoptively trans‐
ferred Tregs was comparable in the absence of IL‐2, the expansion 
of Kd‐specific Tregs was significantly higher after IL‐2 treatment. 
These data suggest that antigen recognition by Tregs is necessary 
for the synergistic effects of IL‐2 therapy to be seen. This was fur‐
ther confirmed by transferring B6‐S and B6‐Kd Treg lines to BL/6 
mice transplanted with third‐party mismatched CBA donor skin 
(H‐2k). Following the same treatment regimen described in Figure 2, 
the distribution of adoptively transferred Tregs was analyzed on day 
10 after transplantation in the spleen, draining lymph nodes, skin, 
and blood (Figure 5B). The frequencies of the transferred Treg lines 
among the whole Treg pool increased in a similar proportion by IL‐2 
treatment, indicating comparable proliferative capacities against the 
third‐party allograft.
4  | DISCUSSION
Treg homeostasis is highly dependent on the availability of IL‐2, 
which controls their survival and proliferation through different 
transcriptional programmes.22 Low‐dose IL‐2 therapy has shown in 
multiple animal models and clinical settings to induce the expansion 
of the Treg pool up to 2‐3‐fold and to stabilize their number until IL‐2 
treatment withdrawal.20 Our data have demonstrated that the ex‐
pansion of endogenous Tregs in mice receiving IL‐2c alone or in com‐
bination with adoptive transferred Tregs is similar, indicating that 
the frequency of Tregs is in strict relationship with the amount of 
IL‐2 available and is independent on the exogenous transfer of Tregs. 
This observation suggests that the combination of low‐dose IL‐2 
therapy with adoptive transfer of polyclonal Tregs provides limited 
therapeutic benefit to the IL‐2 treatment alone. However, it should 
be noted that ex vivo polyclonal expansion, although it might not 
increase the frequency of Tregs with donor specificity, can provide 
additional functional properties to Tregs, which can add therapeutic 
F I G U R E  4   Characterization of 
adoptive transferred Tregs in skin 
transplant model. Tregs from different 
tissues were analyzed 6 or 10 days 
after BL/6‐Kd skin transplant to BL/6 
mice receiving no cells, B6‐S or B6‐Kd 
Tregs in combination or not with IL‐2c. 
A, Representative FOXP3 expression 
histogram of circulating CD4 + T cells 
(left) and frequency of FOXP3 + among 
transferred CD45.2 + cells in blood 6 
and 10 days after skin transplant (right). 
B, Frequency of ICOS+, CTLA4 + , 
CD39 +, and CD25 mean fluorescence 
intensity (MFI) on endogenous (CD45.1) 
and exogenous transferred (CD45.2) 
Tregs in draining lymph nodes 10 days 
after transplantation. Results represent 
mean ± standard error of the mean of 
two independent experiments. B6‐Kd, 
Kd‐specific BL/6; B6‐S, Self‐specific 
BL/6; CTLA4, cytotoxic T‐lymphocyte‐
associated protein 4; FOXP3, Forkhead 
box p3+; ICOS, inducible costimulator; 
IL‐2, interleukin‐2; IL‐2c, interleukin‐2 
complexes; PBS, phosphate‐buffered 
saline; Tregs, regulatory T cells. *P < .05, 
**P < .01, ***P < .001, ****P < .0001
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improvement to the IL‐2 therapy, such as enhancing the expression 
of chemokine receptor to increase specific tissue trafficking and re‐
storing or adding suppressive properties to endogenous Tregs that 
are often dysfunctional in disease patients.23
The combination of IL‐2c and adoptive transfer of donor‐spe‐
cific Tregs significantly improves the therapeutic efficacy of both 
individual treatments in a model of skin transplantation. Phenotypic 
analysis of Tregs in recipient mice showed enhanced expression of 
the CTLA4 and inducible costimulator by donor‐specific Tregs, pref‐
erentially in the skin graft and draining lymph nodes, suggesting 
increased activation and suppressive function due to antigen recog‐
nition. The reported phenotypical changes induced by IL‐2 therapy 
on Tregs 15 were not significantly observed in the IL‐2c treated mice 
10 days after skin transplantation due to the elapsed time from the 
last dose (day 3 after engraftment). Therefore, our data suggest that 
the improvement on graft survival in the combinational therapy is 
mainly related to the preferential expansion of donor‐specific Tregs 
by IL‐2c in graft‐associated tissues.
Our study further supports the importance of donor‐specific 
Tregs to regulate alloimmune responses and it shows limited ef‐
fect of IL‐2 therapy by itself. However, the reduced frequency of 
allograft‐reactive Tregs early after transplantation and the short 
IL‐2 treatment provided in our model did not allow the sufficient ex‐
pansion of endogenous donor‐specific Tregs. Therefore, we cannot 
exclude that IL‐2 therapy in combination with immunosuppressive 
drugs for prolonged periods of time could slowly augment the en‐
dogenous donor‐specific Treg pool by continuous antigen recogni‐
tion. The application of new immunomonitoring approaches such 
as TCR repertoire analysis of donor‐reactive T cells could provide 
further information about the homeostatic characteristics of Tregs 
during IL‐2 therapy in clinical settings.24,25
The fate of adoptive transferred Tregs in the clinic remains 
mostly unknown due to the suboptimal cell tracking methods cur‐
rently available, limiting the assessment of cell survival, allograft 
trafficking and functional stability. It has been reported that tissue 
inflammation and other microenvironment cues such as the use of 
CNIs can compromise Treg homeostasis,26 and consequently, limit 
the survival and stability of adoptively transferred Tregs in non‐
human primates.27,28 Therefore, complementary strategies to in‐
crease Treg expansion and secure their stability are indispensable 
in the transplantation setting, especially using donor‐specific Tregs, 
as the loss of their functional stability could lead to highly patho‐
genic responses to the allograft. Current reports from clinical tri‐
als using deuterium‐labelled Tregs during ex vivo expansion have 
F I G U R E  5   IL‐2c amplifies the number of adoptive transferred Kd‐specific Tregs after skin transplantation. A, CFSE‐labeled B6‐S or  
B6‐Kd Tregs were transferred into BL/6 or BL/6Kd mice in combination or not with IL‐2c. Cell proliferation of transferred Tregs was assessed 
3 days after injection by CFSE dilution (left panels) and their proliferation index was calculated using FlowJo V7 Proliferation Tool (right). 
B, Percentages of transferred B6‐S or B6‐Kd Tregs among FOXP3 + cells were analyzed from different tissues 10 days after CBA skin 
transplant to BL/6 mice in the presence (black bars) or not (white bars) of IL‐2c. Results represent mean ± standard error of the mean from 
same experiment. B6‐Kd, Kd‐specific BL/6; B6‐S, Self‐specific BL/6; CFSE, carboxyfluorescein succinimidyl ester; FOXP3, Forkhead box 
p3+; IL‐2, interleukin‐2; IL‐2c, interleukin‐2 complexes; PBS, phosphate‐buffered saline; Treg, regulatory T cell. *P < .05, **P <.01
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demonstrated that transferred Tregs can be detectable up to 1 year 
in autoimmune and transplanted patients.4,5 Although, similar to our 
results, the transferred cells proved to maintain the Treg phenotype 
in circulation, the percentage of Tregs remaining after 2 weeks was 
very little (<3% of total Tregs). Importantly, recent studies have re‐
ported that IL‐2 treatment can significantly expand and restore Treg 
dysfunction in the presence of CNIs treatment,15 and also maintain 
Treg stability in proinflammatory conditions.29 Therefore, the clini‐
cal utility of low‐dose IL‐2 combined with adoptive transfer of allo‐
specific Tregs is particularly suited in transplantation settings where 
CNIs are the main IS drug.
We demonstrate here that IL‐2 treatment promotes a preferen‐
tial expansion of adoptively transferred donor‐specific Tregs after 
skin transplantation leading to a synergistic effect in graft survival. 
However, the intrinsic restrains associated with the use of animal 
models limit the investigation of relevant immune responses import‐
ant in a clinical setting. For instance, the BL/6.Kd into BL/6 model 
limits the analysis to Tregs with indirect allospecificity, because the 
graft does not present the allogenic major histocompatibility com‐
plex class II molecules required to prime Tregs through the direct 
allorecognition pathway. On the other hand, human transplanta‐
tion generally involves high donor‐antigen mismatch and enhanced 
role of alloreactive memory T responses. Therefore, we believe 
that some form of T cell depletion will be essential, in combination 
with Treg therapy, to achieve transplantation tolerance in the clinic. 
Nevertheless, our data suggest that supplementing Treg adminis‐
tration with IL‐2 therapy will enhance their potency and increase 
the utility of this approach. Overall, this study provides novel un‐
derstanding about Treg homeostasis during IL‐2 therapy and further 
highlights the advantage of donor specificity for Tregs immunoregu‐
lation in transplantation therapy.
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